title: Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model.
abstract: Metastatic spread, not primary tumor burden, is the leading cause of breast cancer deaths. For patient prognosis to improve, new systemic adjuvant therapies that are capable of effectively inhibiting the outgrowth of seeded tumor cells after surgical treatment of the primary breast tumor are needed. To facilitate the preclinical development of such therapies, relevant animal models of breast cancer metastasis that can mimic the postsurgical adjuvant setting are required. Here we developed a preclinical xenograft model of breast cancer metastasis where the primary tumor was removed by surgical resection before systemic adjuvant treatment. We used this model to assess the antimetastatic effect of postsurgical dietary intervention with the soy isoflavone genistein. The anticancer activity of genistein has been established in vitro and in vivo, however, few studies have tested the potential of genistein as an antimetastatic therapy. Using our model, we tested the efficacy of adjuvant treatment with genistein to inhibit the outgrowth of metastases postsurgery. To establish primary tumors, human breast carcinoma cells, MDA-MB-435/HAL, were implanted into the mammary fat pad of female nude mice. Primary tumors were left to grow for 5 weeks before being surgically removed. Mice were then randomized into two diet groups: control soy-free diet versus genistein-supplemented diet. Five weeks later, metastatic burden was assessed. Genistein reduced the percent metastatic burden in the lungs by 10-fold. These results indicate that dietary intervention following cancer surgery can affect the outgrowth of seeded tumor cells. The availability of well-characterized, clinically relevant animal models for studying factors that regulate metastatic outgrowth postsurgery will provide an important tool for developing new systemic adjuvant therapies.
authors.affiliation: Department of Pathology, University of Western Ontario, Canada.
authors.forename: Sharon A
authors.initials: SA
authors.lastname: Vantyghem
authors.forename: Sylvia M
authors.initials: SM
authors.lastname: Wilson
authors.forename: Carl O
authors.initials: CO
authors.lastname: Postenka
authors.forename: Waleed
authors.initials: W
authors.lastname: Al-Katib
authors.forename: Alan B
authors.initials: AB
authors.lastname: Tuck
authors.forename: Ann F
authors.initials: AF
authors.lastname: Chambers
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control* / Q000601:surgery; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D019587:Dietary Supplements; D005260:Female; D019833:Genistein / Q000008:administration & dosage*; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis; D023041:Xenograft Model Antitumor Assays
chemical_list: D016588:Anticarcinogenic Agents; D000970:Antineoplastic Agents; D019833:Genistein